CompletedPhase 3NCT04695860
Anti-FGF23 (Burosumab) in Adult Patients With XLH
Studying X-linked hypophosphatemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Wuerzburg University Hospital
- Principal Investigator
- Lothar Seefried, MDUniversity Hospital Wuerzburg
- Intervention
- Burosumab(drug)
- Enrollment
- 36 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2023
Study locations (1)
- Clinical Trial Unit, Orthopedic Department, Wuerzburg University, Würzburg, Germany
Collaborators
Kyowa Kirin, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04695860 on ClinicalTrials.govOther trials for X-linked hypophosphatemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06525636A First-in-human Study of KK8123 in Adults With X-linked HypophosphatemiaKyowa Kirin Co., Ltd.
- ACTIVE NOT RECRUITINGNCT04946409Burden of Disease and Functional Impairment in XLHWuerzburg University Hospital
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT03748966Calcitriol Monotherapy for X-Linked HypophosphatemiaMassachusetts General Hospital
- ACTIVE NOT RECRUITINGNCT03651505X-linked Hypophosphatemia Disease Monitoring ProgramUltragenyx Pharmaceutical Inc
- ACTIVE NOT RECRUITINGNCT03745521Study of Longitudinal Observation for Patient With X-linked Hypophosphatemic Rickets/Osteomalacia in Collaboration With Asian PartnersKyowa Kirin Co., Ltd.
- RECRUITINGNCT03193476Registry for Patients With X-Linked HypophosphatemiaKyowa Kirin Pharmaceutical Development Ltd